ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML).
Yoko Ueno
Employment or Leadership Position - Astellas Pharma (B)
Naoki Kaneko
Employment or Leadership Position - Astellas Pharma
Rika Saito
Employment or Leadership Position - Astellas Pharma
Yutaka Kondoh
Employment or Leadership Position - Astellas Pharma
Itsuro Shimada
Employment or Leadership Position - Astellas Pharma
Masamichi Mori
Employment or Leadership Position - Astellas Pharma
Sadao Kuromitsu
Employment or Leadership Position - Astellas Pharma